Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125643831 | 12564383 | 1 | I | 20160712 | 20160718 | 20160718 | EXP | CA-AMGEN-CANSP2016091078 | AMGEN | 66.00 | YR | E | F | Y | 0.00000 | 20160717 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125643831 | 12564383 | 1 | PS | ENBREL | ETANERCEPT | 1 | Subcutaneous | UNK | U | 103795 | UNKNOWN FORMULATION | ||||||||
| 125643831 | 12564383 | 2 | SS | ACTEMRA | TOCILIZUMAB | 1 | Unknown | 800 MG, Q4WK | 0 | 800 | MG | ||||||||
| 125643831 | 12564383 | 3 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 125643831 | 12564383 | 4 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | UNK | 0 | ||||||||||
| 125643831 | 12564383 | 5 | SS | ORENCIA | ABATACEPT | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 125643831 | 12564383 | 6 | C | ACETYLSALICYLIC ACID | ASPIRIN | 1 | UNK | 0 | |||||||||||
| 125643831 | 12564383 | 7 | C | ERGOCALCIFEROL. | ERGOCALCIFEROL | 1 | UNK | 0 | |||||||||||
| 125643831 | 12564383 | 8 | C | FLOVENT | FLUTICASONE PROPIONATE | 1 | UNK | 0 | |||||||||||
| 125643831 | 12564383 | 9 | C | FOLIC ACID. | FOLIC ACID | 1 | UNK | 0 | |||||||||||
| 125643831 | 12564383 | 10 | C | METRONIDAZOLE. | METRONIDAZOLE | 1 | UNK | 0 | |||||||||||
| 125643831 | 12564383 | 11 | C | PANTOPRAZOLE SODIUM. | PANTOPRAZOLE SODIUM | 1 | Unknown | UNK | 0 | ||||||||||
| 125643831 | 12564383 | 12 | C | RITUXIMAB | RITUXIMAB | 1 | Unknown | 0 | |||||||||||
| 125643831 | 12564383 | 13 | C | ROSUVASTATIN CALCIUM. | ROSUVASTATIN CALCIUM | 1 | Unknown | 0 | TABLET | ||||||||||
| 125643831 | 12564383 | 14 | C | SALBUTAMOL | ALBUTEROL | 1 | 0 | ||||||||||||
| 125643831 | 12564383 | 15 | C | SULFASALAZINE. | SULFASALAZINE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125643831 | 12564383 | 1 | Rheumatoid arthritis |
| 125643831 | 12564383 | 2 | Rheumatoid arthritis |
| 125643831 | 12564383 | 3 | Product used for unknown indication |
| 125643831 | 12564383 | 4 | Product used for unknown indication |
| 125643831 | 12564383 | 5 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125643831 | 12564383 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125643831 | 12564383 | Bone erosion | |
| 125643831 | 12564383 | C-reactive protein increased | |
| 125643831 | 12564383 | Drug hypersensitivity | |
| 125643831 | 12564383 | Hepatitis | |
| 125643831 | 12564383 | Liver disorder | |
| 125643831 | 12564383 | Pruritus | |
| 125643831 | 12564383 | Rash | |
| 125643831 | 12564383 | Red blood cell sedimentation rate increased | |
| 125643831 | 12564383 | Rheumatoid factor positive |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |